Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosgemcitabine palabenamide - Cardiff University/NuCana Biomed

Next Previous
X
Search
Drug Profile

Fosgemcitabine palabenamide - Cardiff University/NuCana Biomed

Alternative Names: Acelarin®; CPF-31; Gemcitabine analog - Nucana; Gemcitabine-phosphoramidate; Gemcitabine-ProTide; MTL-007; NUC 1031

Latest Information Update: 10 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardiff University
  • Developer Imperial College of Science, Technology and Medicine; NuCana
  • Class Antineoplastics; Pyrimidine nucleosides
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Ovarian cancer
  • Phase I/II Solid tumours
  • No development reported Biliary cancer; Bladder cancer; Non-small cell lung cancer

Most Recent Events

  • 10 Jan 2025 No development reported - Phase-III for Biliary cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Canada (IV)
  • 10 Jan 2025 No development reported - Phase-III for Biliary cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Hungary (IV)
  • 10 Jan 2025 No development reported - Phase-III for Biliary cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Italy (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top